A Programme for Risk Assessment and Minimisation of Progressive Multifocal Leukoencephalopathy Developed for Vedolizumab Clinical Trials

INTRODUCTION: Over the past decade, the potential for drug-associated progressive multifocal leukoencephalopathy (PML) has become an increasingly important consideration in certain drug development programmes, particularly those of immunomodulatory biologics. Whether the risk of PML with an investig...

Descripción completa

Detalles Bibliográficos
Autores principales: Parikh, Asit, Stephens, Kristin, Major, Eugene, Fox, Irving, Milch, Catherine, Sankoh, Serap, Lev, Michael H., Provenzale, James M., Shick, Jesse, Patti, Mark, McAuliffe, Megan, Berger, Joseph R., Clifford, David B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061428/
https://www.ncbi.nlm.nih.gov/pubmed/29737503
http://dx.doi.org/10.1007/s40264-018-0669-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061428/
https://www.ncbi.nlm.nih.gov/pubmed/29737503
http://dx.doi.org/10.1007/s40264-018-0669-8

Ejemplares similares